Compare UROY & MASS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UROY | MASS |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 404.6M | 364.3M |
| IPO Year | 2026 | 2020 |
| Metric | UROY | MASS |
|---|---|---|
| Price | $4.14 | $9.77 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 3.5M | 280.6K |
| Earning Date | 03-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 125.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $56,197,000.00 |
| Revenue This Year | $279.20 | $19.44 |
| Revenue Next Year | N/A | $18.63 |
| P/E Ratio | $1,584.46 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.51 | $5.03 |
| 52 Week High | $5.52 | $9.34 |
| Indicator | UROY | MASS |
|---|---|---|
| Relative Strength Index (RSI) | 73.94 | 73.30 |
| Support Level | $3.40 | $7.57 |
| Resistance Level | $4.48 | N/A |
| Average True Range (ATR) | 0.27 | 0.50 |
| MACD | 0.13 | 0.23 |
| Stochastic Oscillator | 91.37 | 93.69 |
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is acquiring and assembling a portfolio of royalties, investing in companies with exposure to uranium and physical uranium. The Company also engages in the purchase and sale of physical uranium.
908 Devices Inc develops a suite of purpose-built handheld devices for point-of-need chemical analysis. Leveraging mass spectrometry, optical spectroscopy, analytics and machine learning technologies, the company makes devices that are smaller and more accessible than conventional laboratory instruments. Its devices, including MX908, ThreatID, XplorIR and VipIR, are used to analyze unknown materials and provide actionable answers in health, safety and defense technology applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure and security threats. The company reimagines mass spectrometry technology by developing smaller, lower-cost and simpler-to-operate devices compared to conventional instruments, and generates maximum revenue from the United States.